**Acquisition Cost**

Not applicable.

**FDA Approval Designation**

On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT has FDA Breakthrough Therapy and Fast Track Designations for the treatment of patients with unresectable or metastatic GIST harboring PDGFRA D842V mutations[[1]](#footnote-1) and was approved under Priority Review.[[2]](#footnote-2)

**Expected Utilization**

GIST is a rare, genomically driven sarcoma of the gastrointestinal (GI) tract. There are approximately 5,000 patients diagnosed with primary GIST in the U.S. annually, and approximately five to six percent of patients with newly diagnosed GIST have PDGFRA exon 18 mutations. The most common PDGFRA exon 18 mutation is the D842V mutation, which is resistant to all other approved therapies. These incidence estimates are based on external data sources, and GIST epidemiology data are imprecise. We do not have state-specific estimates for anticipated AYVAKIT utilization.

**Marketing Plan Disclosure**

The company’s marketing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure.

**Pricing Plan Disclosure**

The company’s pricing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure.

**Launch Price**

The wholesale acquisition cost (WAC) for a 30-day supply of AYVAKIT is $32,000.

1. Data on file (DOF-REF-00206). Blueprint Medicines Corporation, Cambridge, MA. 2019. [↑](#footnote-ref-1)
2. Data on file (DOF-REF-00263). Blueprint Medicines Corporation, Cambridge, MA. 2019. [↑](#footnote-ref-2)